Roman Rüdiger1, Franziska Geiser2, Manuel Ritter3, Peter Brossart4, Mignon-Denise Keyver-Paik5, Andree Faridi5, Hartmut Vatter6, Friedrich Bootz7, Jennifer Landsberg8, Jörg C Kalff9, Ulrich Herrlinger10, Glen Kristiansen11, Torsten Pietsch12, Stefan Aretz13, Daniel Thomas14, Lukas Radbruch15, Franz-Josef Kramer16, Christian P Strassburg17, Maria Gonzalez-Carmona17, Dirk Skowasch18, Markus Essler19, Matthias Schmid20, Jennifer Nadal20, Nicole Ernstmann21, Amit Sharma1, Benjamin Funke1, Ingo G H Schmidt-Wolf22. 1. Department of Integrated Oncology, CIO Bonn, Center for Integrated Oncology ABCD, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. 2. Institute of Psychosomatic Medicine and Psychotherapy, University Hospital Bonn, Bonn, Germany. 3. Department of Urology, University Hospital Bonn, Bonn, Germany. 4. Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany. 5. Department of Senology and certified Breast Center, University Hospital Bonn, Bonn, Germany. 6. Department of Neurosurgery, University Hospital Bonn, Bonn, Germany. 7. Department of Otorhinolaryngology, University Hospital Bonn, Bonn, Germany. 8. Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany. 9. Department of Surgery, University Hospital Bonn, Bonn, Germany. 10. Department of Neurology, University Hospital Bonn, Bonn, Germany. 11. Institute of Pathology, University Hospital Bonn, Bonn, Germany. 12. Department of Neuropathology, University Hospital Bonn, Bonn, Germany. 13. Institute of Human Genetics, University Hospital Bonn, Bonn, Germany. 14. Department of Radiology, University Hospital Bonn, Bonn, Germany. 15. Department of Palliative Medicine, University Hospital Bonn, Bonn, Germany. 16. Department of Oral and Maxillofacial Plastic Surgery, University Hospital Bonn, Bonn, Germany. 17. Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany. 18. Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. 19. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. 20. Institute for Medical Biometry, Computer Science and Epidemiology, University Hospital Bonn, Bonn, Germany. 21. Center for Health Communication and Health Services Research, Department of Psychosomatic Medicine and Psychotherapy, University Hospital Bonn, Bonn, Germany. 22. Department of Integrated Oncology, CIO Bonn, Center for Integrated Oncology ABCD, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Ingo.Schmidt-Wolf@ukb.uni-bonn.de.
Abstract
BACKGROUND: Immigration has taken the central stage in world politics, especially in the developed countries like Germany, where the continuous flow of immigrants has been well documented since 1960s. Strikingly, emerging data suggest that migrant patients have a poorer response to the treatment and lower survival rates in their new host country, raising concerns about health disparities. Herein, we present our investigation on the treatment response rate and cancer survival in German patients with and without an immigrant background that were treated at our comprehensive cancer center in Germany. METHODS: Initially, we considered 8162 cancer patients treated at the Center for Integrated Oncology (CIO), University Hospital Bonn, Germany (April 2002-December 2015) for matched-pair analysis. Subsequently, the German patients with a migration background and those from the native German population were manually identified and catalogued using a highly specific name-based algorithm. The clinical parameters such as demographic characteristics, tumor characteristics, defined staging criteria, and primary therapy were further adjusted. Using these stringent criteria, a total of 422 patients (n = 211, Germans with migration background; n = 211, native German population) were screened to compare for the treatment response and survival rates (i.e., 5-year overall survival, progression-free survival, and time to progression). RESULTS: Compared to the cohort with migration background, the cohort without migration background was slightly older (54.9 vs. 57.9 years) while having the same sex distribution (54.5% vs. 55.0% female) and longer follow-up time (36.9 vs. 42.6 months). We did not find significant differences in cancer survival (5-year overall survival, P = 0.771) and the response rates (Overall Remission Rate; McNemar's test, P = 0.346) between both collectives. CONCLUSION: Contrary to prior reports, we found no significant differences in cancer survival between German patients with immigrant background and native German patients. Nevertheless, the advanced treatment protocols implemented at our comprehensive cancer center may possibly account for the low variance in outcome. To conduct similar studies with a broader perspective, we propose that certain risk factors (country-of-origin-specific infections, dietary habits, epigenetics for chronic diseases etc.) should be considered, specially in the future studies that will recruit new arrivals from the 2015 German refugee crisis.
BACKGROUND: Immigration has taken the central stage in world politics, especially in the developed countries like Germany, where the continuous flow of immigrants has been well documented since 1960s. Strikingly, emerging data suggest that migrant patients have a poorer response to the treatment and lower survival rates in their new host country, raising concerns about health disparities. Herein, we present our investigation on the treatment response rate and cancer survival in German patients with and without an immigrant background that were treated at our comprehensive cancer center in Germany. METHODS: Initially, we considered 8162 cancerpatients treated at the Center for Integrated Oncology (CIO), University Hospital Bonn, Germany (April 2002-December 2015) for matched-pair analysis. Subsequently, the German patients with a migration background and those from the native German population were manually identified and catalogued using a highly specific name-based algorithm. The clinical parameters such as demographic characteristics, tumor characteristics, defined staging criteria, and primary therapy were further adjusted. Using these stringent criteria, a total of 422 patients (n = 211, Germans with migration background; n = 211, native German population) were screened to compare for the treatment response and survival rates (i.e., 5-year overall survival, progression-free survival, and time to progression). RESULTS: Compared to the cohort with migration background, the cohort without migration background was slightly older (54.9 vs. 57.9 years) while having the same sex distribution (54.5% vs. 55.0% female) and longer follow-up time (36.9 vs. 42.6 months). We did not find significant differences in cancer survival (5-year overall survival, P = 0.771) and the response rates (Overall Remission Rate; McNemar's test, P = 0.346) between both collectives. CONCLUSION: Contrary to prior reports, we found no significant differences in cancer survival between German patients with immigrant background and native German patients. Nevertheless, the advanced treatment protocols implemented at our comprehensive cancer center may possibly account for the low variance in outcome. To conduct similar studies with a broader perspective, we propose that certain risk factors (country-of-origin-specific infections, dietary habits, epigenetics for chronic diseases etc.) should be considered, specially in the future studies that will recruit new arrivals from the 2015 German refugee crisis.
Authors: Marie K Budde; Walther Kuhn; Mignon-Denise Keyver-Paik; Friedrich Bootz; Jörg C Kalff; Stefan C Müller; Thomas Bieber; Peter Brossart; Hartmut Vatter; Ulrich Herrlinger; Dieter C Wirtz; Hans H Schild; Glen Kristiansen; Thorsten Pietsch; Stefan Aretz; Franziska Geiser; Lukas Radbruch; Rudolf H Reich; Christian P Strassburg; Dirk Skowasch; Markus Essler; Nicole Ernstmann; Jennifer Landsberg; Benjamin Funke; Ingo G H Schmidt-Wolf Journal: BMC Cancer Date: 2019-10-30 Impact factor: 4.430
Authors: Franz X Mayr; Alexander Bertram; Holger Cario; Michael C Frühwald; Hans-Jürgen Groß; Arndt Groening; Stefanie Grützner; Thomas Gscheidmeier; Reinhard Hoffmann; Alexander Krebs; Hans-Georg Ruf; Antje Torge; Joachim Woelfle; Oliver Razum; Manfred Rauh; Markus Metzler; Jakob Zierk Journal: Sci Rep Date: 2021-10-26 Impact factor: 4.379